A study to evaluate THB001 in adult patients with chronic cold urticaria

illustrative image

Third Harmonic Bio, Inc is starting a new clinical trial of A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria.

This is a phase 1b, open label, non-randomized, sequential dose-escalation, multicenter trial in adult patients with chronic cold urticaria.

The clinical trial starts in September 2022 and will continue throughout September 2023.

Safety as assessed by the incidence and severity of adverse events will be primary outcome measure. Safety evaluations will include analyses of adverse events by treatment group.

For more details: https://ichgcp.net/clinical-trials-registry/NCT05510843.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

A study to evaluate THB001 in adult patients with chronic cold urticaria

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe